<- Go Home
Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Market Cap
AUD 422.5M
Volume
200.2K
Cash and Equivalents
AUD 53.7M
EBITDA
AUD 48.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 243.9M
Profit Margin
58.97%
52 Week High
AUD 7.31
52 Week Low
AUD 3.74
Dividend
N/A
Price / Book Value
0.95
Price / Earnings
-3.47
Price / Tangible Book Value
-3.25
Enterprise Value
AUD 337.4M
Enterprise Value / EBITDA
6.50
Operating Income
-AUD 11.1M
Return on Equity
23.75%
Return on Assets
-0.61
Cash and Short Term Investments
AUD 124.9M
Debt
AUD 39.9M
Equity
AUD 446.2M
Revenue
AUD 413.5M
Unlevered FCF
AUD 42.2M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium